Discontinued — last reported Q3 '23
Applovin Corporation Interest Paid increased by 6550.7% to $97.77M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 93.7%, from $50.48M to $97.77M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 26.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.11M | $15.25M | $29.67M | $28.87M | $33.00M | $45.78M | $58.31M | $67.01M | $51.94M | $65.65M | $64.23M | $71.19M | $73.80M | $75.15M | $50.48M | $2.39M | $97.16M | $1.47M | $97.77M |
| QoQ Change | — | -5.3% | +94.5% | -2.7% | +14.3% | +38.7% | +27.4% | +14.9% | -22.5% | +26.4% | -2.2% | +10.8% | +3.7% | +1.8% | -32.8% | -95.3% | >999% | -98.5% | >999% |
| YoY Change | — | — | — | — | +104.9% | +200.1% | +96.5% | +132.1% | +57.4% | +43.4% | +10.2% | +6.2% | +42.1% | +14.5% | -21.4% | -96.6% | +31.7% | -98.0% | +93.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.